<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Higher-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with del5q carry a poor prognosis </plain></SENT>
<SENT sid="1" pm="."><plain>In this phase 2 trial, 47 patients with higher-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> received lenalidomide 10 mg/day </plain></SENT>
<SENT sid="2" pm="."><plain>International Prognostic Scoring System was high in 60%, intermediate-2 risk in 40%. del 5q was isolated, with one additional and more than one additional abnormality in 19%, 23%, and 58% patients, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Thirteen (27%) patients achieved hematologic response, including 7 hematologic complete remission (CR) (with complete [4] or partial [3] cytogenetic response), 2 marrow CR and 4 hematologic improvement erythroid, and 12 became red blood cell (RBC) transfusion independent, for a median duration of 6.5 months </plain></SENT>
<SENT sid="4" pm="."><plain>Median CR duration was 11.5 months </plain></SENT>
<SENT sid="5" pm="."><plain>Six of 9 (67%) patients with isolated del 5q achieved CR, versus 1 of 11 and none of 27 patients with one or more than one additional abnormality, respectively (P &lt; .001) </plain></SENT>
<SENT sid="6" pm="."><plain>Seven of 20 (35%) with initial platelets more than 100,000/mm(3) obtained CR, compared with none of the 27 with lower platelet counts less than 100,000/mm(3) (P = .001) </plain></SENT>
<SENT sid="7" pm="."><plain>Our data support a potential role of lenalidomide in higher-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with isolated del 5q </plain></SENT>
</text></document>